cantharidin has been researched along with Cancer of Liver in 32 studies
Cantharidin: A toxic compound, isolated from the Spanish fly or blistering beetle (Lytta (Cantharis) vesicatoria) and other insects. It is a potent and specific inhibitor of protein phosphatases 1 (PP1) and 2A (PP2A). This compound can produce severe skin inflammation, and is extremely toxic if ingested orally.
cantharidin : A monoterpenoid with an epoxy-bridged cyclic dicarboxylic anhydride structure secreted by many species of blister beetle, and most notably by the Spanish fly, Lytta vesicatoria. Natural toxin inhibitor of protein phosphatases 1 and 2A.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cantharidin (CTD) is the active ingredient of Chinese medicine, which has been traditionally used in multiple cancers treatment, especially in hepatocellular carcinoma (HCC)." | 8.31 | Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma. ( Deng, XL; Gao, YM; Shi, GT; Wang, HS; Yan, J, 2023) |
| "Sodium cantharidinate/vitamin B6 (SC/VB6) injection, a famous insect-derived traditional Chinese medicine preparation, has been widely applied as a promising adjunctive drug for hepatocellular carcinoma (HCC)." | 7.96 | Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma: Protocol for a meta-analysis. ( Li, J; Liu, X; Zhou, C; Zhu, M, 2020) |
| " In this study, we incorporated a cell-penetrating peptide BR2 onto the surface of a liposome loaded with the anticancer drug cantharidin (CTD) to create a system targeting hepatocellular carcinoma (HCC) cells more efficiently and effectively." | 7.85 | Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. ( Chen, H; Lin, C; Lin, G; Liu, Q; Lu, A; Yang, Z; Zhang, H; Zhang, X, 2017) |
| "The present study was designed to investigate the effect of cantharidin on cell proliferation, ability of selfrenewal, cell cycle arrest and induction of apoptosis in HepG2 hepatocellular carcinoma stem cells (HCSCs)." | 7.83 | Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells. ( Le, AP; Liu, W; Shi, YF; Zhang, LL, 2016) |
| "In vivo, the H22 mouse model of hepatocellular carcinoma was established by treatment with CTD and 5-Fu." | 5.91 | Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response. ( Deng, XL; Gao, YM; Hui Li, Y; Ma, SQ; Shi, GT; Wang, HS; Yan, J, 2023) |
| "Cantharidin (CTD) is the active ingredient of Chinese medicine, which has been traditionally used in multiple cancers treatment, especially in hepatocellular carcinoma (HCC)." | 4.31 | Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma. ( Deng, XL; Gao, YM; Shi, GT; Wang, HS; Yan, J, 2023) |
| "Cantharidin (CTD), the main active component of a poisonous traditional Chinese medicine (PTCM) Mylabris, exhibits highly effective therapy of hepatocellular carcinoma (HCC); however, the severe toxicity of CTD on the digestive and urinary systems prevents its clinical application." | 3.96 | Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine. ( Du, G; Han, G; Jin, Y; Lv, J; Song, S; Wang, Z; Yao, H; Zhang, Y; Zhao, J, 2020) |
| "Sodium cantharidinate/vitamin B6 (SC/VB6) injection, a famous insect-derived traditional Chinese medicine preparation, has been widely applied as a promising adjunctive drug for hepatocellular carcinoma (HCC)." | 3.96 | Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma: Protocol for a meta-analysis. ( Li, J; Liu, X; Zhou, C; Zhu, M, 2020) |
| " In this study, we incorporated a cell-penetrating peptide BR2 onto the surface of a liposome loaded with the anticancer drug cantharidin (CTD) to create a system targeting hepatocellular carcinoma (HCC) cells more efficiently and effectively." | 3.85 | Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma. ( Chen, H; Lin, C; Lin, G; Liu, Q; Lu, A; Yang, Z; Zhang, H; Zhang, X, 2017) |
| " The aim of this study was to prepare and characterize PEGylated liposome of cantharidin and investigate its therapeutic effect on human hepatocellular carcinoma treatment in vitro and in vivo." | 3.85 | Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation. ( Chan, WK; Lin, CC; Liu, KL; Yang, ZJ; Zhang, HQ; Zhang, X, 2017) |
| "The function of sodium cantharidinate on inducing hepatocellular carcinoma cell apoptosis was investigated for the first time." | 3.85 | Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway. ( Ding, YH; Li, HJ; Qiu, W; Sun, WY; Tao, R; Wang, GY; Yan, WQ; Yu, DH, 2017) |
| "The present study was designed to investigate the effect of cantharidin on cell proliferation, ability of selfrenewal, cell cycle arrest and induction of apoptosis in HepG2 hepatocellular carcinoma stem cells (HCSCs)." | 3.83 | Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells. ( Le, AP; Liu, W; Shi, YF; Zhang, LL, 2016) |
| " The present study aimed to investigate the molecular events underlying inhibitory effect of N-benzylcantharidinamide, a novel synthetic analog of cantharidin, on matrix metalloproteinase-9 (MMP-9)-mediated invasion in highly metastatic hepatocellular carcinoma Hep3B cells." | 3.80 | A novel cantharidin analog N-benzylcantharidinamide reduces the expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic translocation of HuR. ( Choi, HJ; Choi, JY; Chung, TW; Eun, JS; Ha, KT; Han, CW; Han, YT; Jeong, HS; Kim, SY; Lee, CH; Lee, JY, 2014) |
| "A novel series of TCM-platinum complexes [Pt(C8H8O5)(NH2R)2] 1-5, designed from incorporating demethylcantharidin, a modified component from a traditional Chinese medicine (TCM) with a platinum moiety was found to circumvent cisplatin resistance in mouse leukemia and human hepatocellular carcinoma." | 3.73 | Synergistic interaction between platinum-based antitumor agents and demethylcantharidin. ( Au-Yeung, SC; Ho, YP; To, KK, 2005) |
| " Water solubility and bioavailability could be improved by opening the five fivemembered anhydride ring to form carboxylic acid, salt, amide, and ester derivatives." | 3.01 | Exploring Cantharidin and its Analogues as Anticancer Agents: A Review. ( Deng, L; Du, K; Fan, G; Li, S; Wu, X, 2023) |
| "In vivo, the H22 mouse model of hepatocellular carcinoma was established by treatment with CTD and 5-Fu." | 1.91 | Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response. ( Deng, XL; Gao, YM; Hui Li, Y; Ma, SQ; Shi, GT; Wang, HS; Yan, J, 2023) |
| "Liver cancer is a common malignant tumor worldwide, and its morbidity and mortality increase each year." | 1.51 | Development of 11-DGA-3- ( Ning, S; Xia, X; Zhou, L; Zhu, K; Zou, M, 2019) |
| "After treating the hepatoma cell line 7721 with triptolide(9, 18, or 36 μg/mL) and/or sodium cantharidinate (2, 5, or 10 μg/mL), cell viability assay and apoptosis were examined by MTT and flocytometry, respectively." | 1.43 | [Combination of triptolide with sodium cantharidinate synergistically enhances apoptosis on hepatoma cell line 7721]. ( Dong, Z; Han, L; Ju, Y; Pan, X; Wang, G; Wang, M; Zhou, Y, 2016) |
| "To study the synergistic effect on hepatoma cell(SMMC-7721) and the reduction killing effect on normal liver cells(LO-2) treated with sodium cantharidinate (SCA) in combination with fluorouracil(5-FU) or cisplatin(DDP) as well as the related mechanism." | 1.40 | [Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism]. ( Chen, MJ; Xu, DQ; Zhang, X; Zhao, FM; Zhao, RL; Zhou, KF, 2014) |
| "Transcatheter arterial embolization (TAE) using hydroxycamptothecin, cantharidin and cisplatin which were mixed thoroughly with lipiodol, combined with large doses interferon and interleukin-2 as adoptive immunotherapy were carried out in the treatment of 48 patients with unresectable advanced stage primary hepatoma, evaluation of therapeutic effect showed that partial remission rate was 54." | 1.29 | [Chinese material medica combined with cisplatin and lipiodol through transcatheter arterial embolization in the treatment of primary hepatoma]. ( Yu, ZJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.13) | 18.2507 |
| 2000's | 3 (9.38) | 29.6817 |
| 2010's | 19 (59.38) | 24.3611 |
| 2020's | 9 (28.13) | 2.80 |
| Authors | Studies |
|---|---|
| Yeh, CB | 2 |
| Su, CJ | 1 |
| Hwang, JM | 1 |
| Chou, MC | 1 |
| Sun, S | 1 |
| Shang, E | 1 |
| Ju, A | 1 |
| Li, Y | 2 |
| Wu, Q | 1 |
| Li, Q | 1 |
| Yang, Y | 1 |
| Guo, Y | 1 |
| Yang, D | 1 |
| Lv, S | 1 |
| Xu, Y | 1 |
| Wang, M | 2 |
| Ning, S | 3 |
| Yang, Z | 2 |
| Zhou, L | 3 |
| Xia, X | 3 |
| Li, S | 1 |
| Wu, X | 1 |
| Fan, G | 1 |
| Du, K | 2 |
| Deng, L | 1 |
| Yan, J | 2 |
| Deng, XL | 2 |
| Ma, SQ | 1 |
| Hui Li, Y | 1 |
| Gao, YM | 2 |
| Shi, GT | 2 |
| Wang, HS | 2 |
| Lu, S | 1 |
| Huang, J | 1 |
| Zhang, J | 1 |
| Wu, C | 1 |
| Huang, Z | 1 |
| Tao, X | 1 |
| You, L | 1 |
| Stalin, A | 1 |
| Chen, M | 1 |
| Li, J | 3 |
| Tan, Y | 1 |
| Wu, Z | 1 |
| Geng, L | 1 |
| Li, Z | 1 |
| Fan, Q | 1 |
| Liu, P | 1 |
| Lin, Y | 1 |
| Zhao, C | 1 |
| Wu, J | 1 |
| Zou, M | 2 |
| Zhu, K | 2 |
| Liu, S | 1 |
| Zhou, Y | 2 |
| Zhang, X | 4 |
| Yao, H | 1 |
| Zhao, J | 1 |
| Wang, Z | 2 |
| Lv, J | 1 |
| Du, G | 1 |
| Jin, Y | 1 |
| Zhang, Y | 1 |
| Song, S | 1 |
| Han, G | 1 |
| Zhu, M | 1 |
| Liu, X | 1 |
| Zhou, C | 1 |
| Lin, C | 1 |
| Lu, A | 1 |
| Lin, G | 1 |
| Chen, H | 1 |
| Liu, Q | 2 |
| Zhang, H | 1 |
| Lin, CC | 1 |
| Chan, WK | 1 |
| Liu, KL | 1 |
| Yang, ZJ | 1 |
| Zhang, HQ | 1 |
| Tao, R | 1 |
| Sun, WY | 1 |
| Yu, DH | 1 |
| Qiu, W | 1 |
| Yan, WQ | 1 |
| Ding, YH | 1 |
| Wang, GY | 1 |
| Li, HJ | 1 |
| Feng, IC | 1 |
| Hsieh, MJ | 1 |
| Chen, PN | 1 |
| Hsieh, YH | 1 |
| Ho, HY | 1 |
| Yang, SF | 1 |
| Chen, S | 1 |
| Qu, X | 1 |
| Wan, P | 1 |
| Li, QW | 1 |
| Guo, F | 1 |
| Bai, L | 1 |
| Hu, Z | 1 |
| Tan, W | 1 |
| Wen, SQ | 1 |
| Chen, Q | 1 |
| Hu, M | 1 |
| Lee, JY | 1 |
| Chung, TW | 1 |
| Choi, HJ | 1 |
| Lee, CH | 1 |
| Eun, JS | 1 |
| Han, YT | 1 |
| Choi, JY | 1 |
| Kim, SY | 1 |
| Han, CW | 1 |
| Jeong, HS | 1 |
| Ha, KT | 1 |
| Zhang, W | 1 |
| Ma, YZ | 1 |
| Song, L | 1 |
| Wang, CH | 1 |
| Qi, TG | 1 |
| Shao, GR | 1 |
| Shao, H | 1 |
| Hong, G | 1 |
| Luo, X | 1 |
| Zhao, RL | 1 |
| Chen, MJ | 1 |
| Zhao, FM | 1 |
| Xu, DQ | 1 |
| Zhou, KF | 1 |
| Le, AP | 1 |
| Zhang, LL | 1 |
| Liu, W | 1 |
| Shi, YF | 1 |
| Wu, Y | 2 |
| Zhou, D | 2 |
| Zhang, Q | 1 |
| Xie, Z | 1 |
| Chen, X | 1 |
| Jing, X | 2 |
| Huang, Y | 2 |
| Pan, X | 1 |
| Dong, Z | 1 |
| Han, L | 1 |
| Ju, Y | 1 |
| Wang, G | 1 |
| Liu, Y | 1 |
| Li, X | 2 |
| Zou, Q | 1 |
| Liu, L | 1 |
| Zhu, X | 1 |
| Jia, Q | 1 |
| Wang, L | 1 |
| Yan, R | 1 |
| Zheng, LH | 1 |
| Bao, YL | 1 |
| Yu, CL | 1 |
| Meng, X | 1 |
| Li, YX | 1 |
| Wu, ZM | 1 |
| Qi, XH | 1 |
| Zhang, F | 1 |
| Lin, QY | 1 |
| Li, SK | 1 |
| Zhao, YL | 1 |
| Wang, PP | 1 |
| Chen, MM | 1 |
| Xiao, H | 1 |
| Meng, F | 1 |
| To, KK | 1 |
| Ho, YP | 2 |
| Au-Yeung, SC | 2 |
| Yu, CW | 1 |
| Li, KK | 1 |
| Pang, SK | 1 |
| Yu, ZJ | 1 |
2 reviews available for cantharidin and Cancer of Liver
| Article | Year |
|---|---|
Exploring Cantharidin and its Analogues as Anticancer Agents: A Review.
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Humans; Liposomes; Liver Neoplasms | 2023 |
The anti-hepatocellular carcinoma effect of Aidi injection was related to the synergistic action of cantharidin, formononetin, and isofraxidin through BIRC5, FEN1, and EGFR.
Topics: Animals; Cantharidin; Carcinoma, Hepatocellular; ErbB Receptors; Flap Endonucleases; Humans; Liver N | 2024 |
1 trial available for cantharidin and Cancer of Liver
| Article | Year |
|---|---|
[Efficacy of cantharidin combined with transcatheter arterial embolization for primary hepatocellular carcinoma].
Topics: Adult; Aged; Cantharidin; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Live | 2010 |
29 other studies available for cantharidin and Cancer of Liver
| Article | Year |
|---|---|
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2010 |
Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: An in vivo and in vitro study.
Topics: Animals; Cantharidin; Cell Line, Tumor; Female; Hyaluronic Acid; Lipids; Liver Neoplasms; Male; Mice | 2021 |
Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Cantharidin; Carcinoma, Hepatocellular; Drug Carriers; Emulsions; Folic Acid; | 2022 |
Cantharidin suppresses hepatocellular carcinoma development by regulating EZH2/H3K27me3-dependent cell cycle progression and antitumour immune response.
Topics: Animals; Cantharidin; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Epigenesis, Genetic; | 2023 |
Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
Topics: Animals; Cantharidin; Carcinoma, Hepatocellular; Computational Biology; Fatty Acids; Gene Expression | 2023 |
Development of 11-DGA-3-
Topics: Animals; Antineoplastic Agents; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survi | 2019 |
18-GA-Suc Modified Liposome Loading Cantharidin for Augmenting Hepatic Specificity: Preparation, Characterization, Antitumor Effects, and Liver-Targeting Efficiency.
Topics: Cantharidin; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Tissue Distribution | 2020 |
Enhanced anticancer efficacy of cantharidin by mPEG-PLGA micellar encapsulation: An effective strategy for application of a poisonous traditional Chinese medicine.
Topics: Antineoplastic Agents; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Carriers; Huma | 2020 |
Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma: Protocol for a meta-analysis.
Topics: Cantharidin; Carcinoma, Hepatocellular; China; Drug Therapy, Combination; Humans; Immune System; Inj | 2020 |
Liposomes equipped with cell penetrating peptide BR2 enhances chemotherapeutic effects of cantharidin against hepatocellular carcinoma.
Topics: Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Delivery S | 2017 |
Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation.
Topics: Animals; Antineoplastic Agents; Cantharidin; Carcinoma, Hepatocellular; Cell Proliferation; Cell Sur | 2017 |
Sodium cantharidinate induces HepG2 cell apoptosis through LC3 autophagy pathway.
Topics: Apoptosis; Autophagy; Cantharidin; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme Inhibitors; | 2017 |
Cantharidic acid induces apoptosis through the p38 MAPK signaling pathway in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Casp | 2018 |
Norcantharidin inhibits pre-replicative complexes assembly of HepG2 cells.
Topics: Antineoplastic Agents; Biological Transport; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; C | 2013 |
Experimental study on the inhibitory effect of sodium cantharidinate on human hepatoma HepG2 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Proliferatio | 2014 |
A novel cantharidin analog N-benzylcantharidinamide reduces the expression of MMP-9 and invasive potentials of Hep3B via inhibiting cytosolic translocation of HuR.
Topics: Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytosol; ELAV Proteins; Humans; Imides; Li | 2014 |
Effect of cantharidins in chemotherapy for hepatoma: a retrospective cohort study.
Topics: Cantharidin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Foll | 2014 |
Evaluation of sodium cantharidinate/vitamin B6 in the treatment of primary liver cancer.
Topics: Adult; Cantharidin; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Huma | 2014 |
[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplati | 2014 |
Cantharidin inhibits cell proliferation and induces apoptosis through G2/M phase cell cycle arrest in hepatocellular carcinoma stem cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cantharidin; Carcinoma, Hepatocellular; Cel | 2016 |
Dual-Sensitive Charge-Conversional Polymeric Prodrug for Efficient Codelivery of Demethylcantharidin and Doxorubicin.
Topics: Animals; Antibiotics, Antineoplastic; Cantharidin; Carcinoma, Hepatocellular; Doxorubicin; Drug Deli | 2016 |
[Combination of triptolide with sodium cantharidinate synergistically enhances apoptosis on
hepatoma cell line 7721].
Topics: Apoptosis; Cantharidin; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Diterpenes; Down-Reg | 2016 |
[Inhibitory effect of magnesium cantharidate on human hepatoma SMMC-7721 cell proliferation by blocking MAPK signaling pathway].
Topics: Antineoplastic Agents; Cantharidin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; | 2017 |
Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cantharidin; Carcinoma, Hepatocellular; Cel | 2008 |
Synthesis, interaction with DNA and bovine serum albumin of the transition metal complexes of demethylcantharate and 2-aminobenzothiazole.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cantharidin; Carcinoma, Hepatocellular; Cattle; Cell | 2012 |
A polymer-(tandem drugs) conjugate for enhanced cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cantharidin; Cell Line, Tumor; Liver Neopla | 2013 |
Synergistic interaction between platinum-based antitumor agents and demethylcantharidin.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Body Weight; Cantharidin; Carboplatin; Carcin | 2005 |
Anticancer activity of a series of platinum complexes integrating demethylcantharidin with isomers of 1,2-diaminocyclohexane.
Topics: Antineoplastic Agents; Apoptosis; Cantharidin; Carboplatin; Carcinoma, Hepatocellular; Cell Cycle; C | 2006 |
[Chinese material medica combined with cisplatin and lipiodol through transcatheter arterial embolization in the treatment of primary hepatoma].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cantharidin; Carcinoma, Hepatocellular | 1993 |